Managing hematologic toxicities.

摘要: This overview of the hematologic toxicities cancer chemotherapy addresses frequency and clinical significance neutropenia, anemia, thrombocytopenia attempts to provide evidence-based guidelines, based on trials, for use cytokine growth factors transfusion support. The current emphasis high-dose dose-dense increases need close attention amelioration ofhematologic toxicities. latter is highly dependent upon appropriate judicious Although these supportive agents may be relatively nontoxic, it important understand their potential side effects them only when warranted by studies.